Totally Implantable Access Ports

Completed

• Conditions: Solid tumours; Cancer

• Registration Number: ISRCTN02260579
• Lead Sponsor: European Institute of Oncology (Italy)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-03-31
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 750

Inclusion Criteria

1. Patients (aged 18 - 75 years, either sex) bearing solid tumours who are candidate to chemotherapy treatment for at least 4 months
2. Informed signed consent
3. Performance status 0 - 2 (according to Eastern Cooperative Oncology Group [ECOG] score)
4. Platelets greater than 50,000/mm^3
5. Prothrombin time (quick) greater than 60%
6. White blood cells greater than 2500/mm^3
7. Life expectancy greater than 6 months

Exclusion Criteria

1. Severe hepatic failure (ascites, portal hypertension, jaundice or encephalopathy)
2. Renal failure (haemodyalisis and creatinine greater than 2.5 mg/dL)
3. Active infections
4. Coagulopathy
5. Inability to give an informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified